B. Riley Predicts Electromed’s Q3 Earnings (NYSE:ELMD)

Electromed, Inc. (NYSE:ELMD) – Investment analysts at B. Riley issued their Q3 2025 earnings estimates for shares of Electromed in a note issued to investors on Wednesday, February 19th. B. Riley analyst K. Bauser forecasts that the company will post earnings per share of $0.19 for the quarter. B. Riley currently has a “Strong-Buy” rating on the stock. B. Riley also issued estimates for Electromed’s Q4 2025 earnings at $0.22 EPS, FY2025 earnings at $0.80 EPS, Q1 2026 earnings at $0.20 EPS, Q2 2026 earnings at $0.22 EPS, Q3 2026 earnings at $0.26 EPS, Q4 2026 earnings at $0.31 EPS, FY2026 earnings at $1.00 EPS and FY2027 earnings at $1.16 EPS.

Separately, StockNews.com cut shares of Electromed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

Electromed Stock Performance

ELMD stock opened at $26.76 on Monday. Electromed has a one year low of $13.74 and a one year high of $35.56. The stock has a market capitalization of $228.99 million, a PE ratio of 35.68 and a beta of 0.33. The company has a fifty day moving average of $31.35 and a 200-day moving average of $25.58.

Hedge Funds Weigh In On Electromed

Several hedge funds have recently added to or reduced their stakes in ELMD. Arrowstreet Capital Limited Partnership increased its holdings in Electromed by 261.0% during the 4th quarter. Arrowstreet Capital Limited Partnership now owns 114,579 shares of the company’s stock valued at $3,386,000 after acquiring an additional 82,839 shares in the last quarter. Raymond James Financial Inc. purchased a new position in Electromed during the 4th quarter valued at about $1,760,000. Sowell Financial Services LLC purchased a new position in Electromed during the 4th quarter valued at about $1,518,000. Lazard Asset Management LLC increased its holdings in Electromed by 19,860.8% during the 4th quarter. Lazard Asset Management LLC now owns 47,906 shares of the company’s stock valued at $1,415,000 after acquiring an additional 47,666 shares in the last quarter. Finally, Two Sigma Investments LP purchased a new position in Electromed during the 4th quarter valued at about $1,255,000. 40.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Electromed

In other Electromed news, Director Andrew Summers sold 17,463 shares of the firm’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $30.09, for a total transaction of $525,461.67. Following the completion of the transaction, the director now directly owns 189,838 shares in the company, valued at approximately $5,712,225.42. This trade represents a 8.42 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kathleen Skarvan sold 8,640 shares of the firm’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $32.25, for a total transaction of $278,640.00. Following the transaction, the director now owns 71,576 shares of the company’s stock, valued at $2,308,326. This trade represents a 10.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 163,812 shares of company stock worth $4,728,773 over the last 90 days. Company insiders own 14.00% of the company’s stock.

Electromed Company Profile

Electromed, Inc develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions.